Nuzenio

Tenax Therapeutics Announces

Tenax Therapeutics Announces news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 8 latest news signals 6 publisher sources 100/100 entity strength

Latest news

TNX-103 Misses Primary Endpoint in Phase 3 LEVEL PH-HFpEF Trial - HCPLiveHCPLive · Mon, 10 Aug 2026 15:03:24 GMTTenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF - Investing News NetworkInvesting News Network · Mon, 10 Aug 2026 12:54:11 GMTOrion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint - The Manila TimesThe Manila Times · Mon, 10 Aug 2026 11:19:58 GMTChardan Capital Initiates Tenax Therapeutics(TENX.US) With Buy Rating, Announces Target Price $27 - MoomooMoomoo · Fri, 31 Jul 2026 20:31:00 GMTTenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewswireGlobeNewswire · Fri, 31 Jul 2026 11:00:00 GMTTenax expects Phase 3 LEVEL trial data in August 2026 - Stock TitanStock Titan · Fri, 31 Jul 2026 07:00:00 GMTTenax Therapeutics (TENX) CEO Giordano reports 1.69M-share, 4.32% stake - Stock TitanStock Titan · Fri, 31 Jul 2026 07:00:00 GMTBlackRock reports 6.4% stake in Tenax Therapeutics (TENX) - Stock TitanStock Titan · Thu, 30 Jul 2026 15:19:20 GMT

Timeline

Mon, 10 Aug 2026 15:03:24 GMTTNX-103 Misses Primary Endpoint in Phase 3 LEVEL PH-HFpEF Trial - HCPLive
Mon, 10 Aug 2026 12:54:11 GMTTenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF - Investing News Network
Mon, 10 Aug 2026 11:19:58 GMTOrion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint - The Manila Times
Fri, 31 Jul 2026 20:31:00 GMTChardan Capital Initiates Tenax Therapeutics(TENX.US) With Buy Rating, Announces Target Price $27 - Moomoo
Fri, 31 Jul 2026 11:00:00 GMTTenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewswire
Fri, 31 Jul 2026 07:00:00 GMTTenax expects Phase 3 LEVEL trial data in August 2026 - Stock Titan

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Tenax Therapeutics Announces.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

6 distinct publisher/source names are currently connected to this entity page.